SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. ALPHA3 is ...

UAB “Atsinaujinančios energetikos investicijos” (the Company) publishes its factsheet, providing information about the Company’s investment portfolio, key events, business strategy, operating segments, and financial indicators as of 30 September 2025. Investment Company In August, the Bank of Lithuania approved AEI’s up to EUR 50,000,000 nominal value Unsecured Fixed Rate Note Programme. Solar projects In September 2025, AEI completed the divestment of its 2.6 MW solar project in Lithuania UAB “Saulės Energ ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: 625. T Cell ...

LUOYANG, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TRUNNANO, a leading global supplier of industrial ceramic materials, recently announced a significant breakthrough in the research, development, and manufacturing of its core product, reaction sintered silicon carbide (SiSiC). Through years of technological development and process optimization, the company has successfully overcome numerous technical challenges that have hindered the performance and reliability of this material, providing a more stable and c ...

Total of seven events in cities across Canada in 2025The Air Canada Foundation and Air Canada partnered with local autism organizations and airports as well as PAL Airlines and Jazz AviationLast event of the year took place yesterday in Vancouver MONTRÉAL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Air Canada and the Air Canada Foundation are celebrating another successful year of their Autism Aviation Days events. These events aim to provide a supportive environment where children on the spectrum can familiarize th ...

2025年10月及1-10月零售额表现 - 2025年10月含税零售额达3470万欧元，同比增长4.9% [1] - 2025年1-10月含税零售额达3.005亿欧元，同比增长5.6% [1] - 分地区看，1-10月立陶宛零售额同比增长7.5%，拉脱维亚增长5.4%，爱沙尼亚下降1.3% [1] 门店网络与经营规模 - 公司目前运营171家门店，其中立陶宛103家、拉脱维亚44家、爱沙尼亚24家 [2] - 门店总营业面积达9.27万平方米，较一年前增加0.8% [2]

The beloved childrenswear brand and the world-renowned ballet company debut a collaboration celebrating the timeless magic of George Balanchine’s The Nutcracker®SECAUCUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model, announced that this holiday season, Gymboree, as part of The Children’s Place family of brands, will de ...

公司核心动态 - 公司发布最新投资者演示文稿并宣布Pantera Capital普通合伙人Cosmo Jiang当选董事会成员 [1] - 公司战略核心是通过生态系统倡导、有纪律的资产积累以及机构级质押的主动国库管理来实现每股SOL最大化 [3] - 新任董事将与管理层合作，专注于在安全的机构框架内通过持有和获取可持续链上收益来复利积累SOL [4] - 公司致力于成为获取SOL的机构级选择，SOL被认为是未来金融系统的首选区块链 [4] 行业与网络表现 - Solana网络在现实世界资产代币化、去中心化金融和支付领域加速普及 [2] - 该网络在去中心化交易所交易量和资产发行市场份额方面领先所有第一层区块链，年初至今交易量超过230亿次，活跃钱包数量达230万个 [2] - Solana上的稳定币交易量因与PayPal、Stripe和Western Union的整合而达到创纪录水平，其稳定币总市值目前超过145亿美元 [2] 公司背景与定位 - 公司是全球最大的专注于Solana的数字资产国库之一，其运作与Solana生态系统保持长期一致 [3] - 公司是一家上市的数字资产国库，致力于收购和持有Solana，其目标是通过战略性地利用资本市场和链上机会，最大化每股SOL，为公开市场投资者提供直接的SOL增长敞口 [8]

CALGARY, Alberta, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) is pleased to announce completion of its previously-announced preferred share financing (the "Equity Financing"), raising C$26.5 million of additional equity capital, and concluded amendments to its debt agreements to extend maturities by 24 months, defer cash interest obligations through 2026, and adjust financial covenants (the "Debt Amendments"). Equity Financing The Equit ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando. BEAM-101 is an investigational genetically modifie ...